Q2 2016 13F Holders as of 30 Jun 2016
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
444,806,861
-
Total 13F shares
-
8,466,294
-
Share change
-
-583,516
-
Total reported value
-
$3,131,000
-
Price per share
-
$0.37
-
Number of holders
-
36
-
Value change
-
-$217,289
-
Number of buys
-
12
-
Number of sells
-
9
Institutional Holders of PROVECTUS BIOPHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (PVCT) as of Q2 2016
As of 30 Jun 2016,
PROVECTUS BIOPHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (PVCT) was held by
36 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,466,294 shares.
The largest 10 holders included
VANGUARD GROUP INC, Cormorant Asset Management, LLC, GEODE CAPITAL MANAGEMENT, LLC, UBS Group AG, GOLDMAN SACHS GROUP INC, CITADEL ADVISORS LLC, HOME FEDERAL BANK OF TENNESSEE, SABBY MANAGEMENT, LLC, Cutter & CO Brokerage, Inc., and WADE G W & INC.
This page lists
36
institutional shareholders reporting positions in this security
for the Q2 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.